Invus — Full Portfolio

Agenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL.

BiotechHealthtechLexington, US

Garo Armen(Chairman & CEO, Co-founder)Ozer Baysal(Executive Officer)Robert Stein(Executive Officer)Christine Klaskin(Executive Officer)inKaren Valentine(Executive Officer)Steven O'Day(Chief Medical Officer)in

Co-investorsAdvent Life SciencesGrazia Equity GmbHHEALTHCARE ROYALTY PARTNERSOberland CapitalCommodore CapitalLigand Pharmaceuticals+1 more

Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device.

BiotechDigital HealthMental HealthCambridge, US

William Huyett(Executive Officer)Mark G. Currie(Executive Officer)inOle Isacson(Director)Stephanie Lovell(Director)Marsha Fanucci(Director)George Conrades(Director)

Co-investorsPappas CapitalPolaris Partners

Sereact builds AI foundation models that enable industrial robots to perform complex manipulation tasks like warehouse picking and returns handling without retraining.

Advanced ManufacturingAI & Machine LearningDeep TechEnterprise SoftwareQuantum ComputingRoboticsOxford, GB

Ralf Gulde(CEO and co-founder)Marc Tuscher(CTO and co-founder)Gerald Mullally(CEO)

Co-investorsAlpha EdisonBritish Business BankChevron Technology VenturesOxford Science EnterprisesBackstage AB

Leyden Labs develops nasal sprays containing antibodies that target respiratory viruses such as influenza and COVID at the nasal mucosa to prevent initial infection and transmission.

BiotechDeep TechHealthtechLeiden, NL

Koenraad Wiedhaup(Founder & Chief Executive Officer)inRonald Brus(Founder & Chief Growth Officer)inJaap Goudsmit(Founding Scientist and Senior Advisor)inDinko Valerio(Founder and Chair of the Supervisory Board)inJintanat Ananworanich(Chief Medical Officer)inClarissa Koch(Chief Scientific Officer)in

Co-investorsClavystBioF-Prime CapitalGV (Google Ventures)Bluebird VenturesCasdin CapitalEuropean Innovation Council Fund+5 more

Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform.

BiotechHealthtechSan Diego, US

Vijaya Pattabiraman(Co-founder & Chief Technology Officer)inJeffrey Bode(Scientific Co-founder)inFredrik Wiklund(Chief Executive Officer)Christine Siu(Director)Michael Rosenzweig(Director)Bertolt Kreft(Executive Officer)

Co-investorsRA CapitalJohnson & Johnson Innovation – JJDCVersant VenturesVenrockFidelity InvestmentsQatar Investment Authority

Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.

BiotechDigital HealthHealthtechMedical DevicesBurlington, US

Michael E. Mendelsohn(Founder and Chief Strategy Officer)inMichael Mendelsohn, M.D.(Founder)in

Co-investorsBain CapitalDelos CapitalDigitalis VenturesNew Enterprise Associates (NEA)Ascenta CapitalBain Capital Life Sciences+4 more

City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.

BiotechMedical DevicesCambridge, US

Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)

Co-investorsAN Venture PartnersARCH Venture PartnersSofinnova VenturesCasdin CapitalFidelity InvestmentsRock Springs Capital

Coave Therapeutics develops targeted gene therapy vectors using its proprietary ALIGATER platform to deliver therapeutic genes to specific tissues with improved safety and precision.

BiotechDeep TechHealthtechMedical DevicesParis, FR

Co-investorsFund+Kurma PartnersSeroba Life SciencesV-Bio VenturesBpifranceNovo Holdings+1 more

BiotechCambridge, US

Philip Kantoff(Executive Officer, Director)inNeil Bander(Executive Officer, Director)Eric Sullivan(Executive Officer)inAlexander Brown(Executive Officer)in

BoardJake Simson(Director)inTal Zaks(Director)

Co-investorsOrbiMedRA Capital

Datawords operates a network of production studios across local markets to create and deliver localized content at scale for global brands.

AI & Machine LearningEnterprise SoftwareMarketing TechMedia & EntertainmentSector Agnostic

Co-investorsKeensight Capital

Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.

AI & Machine LearningFuture of WorkHR TechTokyo, JP

Kazuki Kamiya(CEO)Satoru Ichihara(COO)Shinya Hayashi(CSO)Hidefumi Iwaki(CFO)Tomohiro Sasaki(Executive Officer (Product Development))

Co-investorsANOBAKACARTA VENTURES, Inc.Spiral VenturesAgent CapitalCasdin CapitalNextech Invest+2 more

BiotechCambridge, US

Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Mark Angelino(Executive Officer)

BoardJason Rhodes(Director)inCatherine Stehman-Breen(Director)Anthony Quinn(Director)

Co-investorsAtlas VentureForesite CapitalF-Prime Capital

Aesthetic-medicine biopharma behind KYBELLA (deoxycholic acid) injection, acquired by Allergan in 2015 for ~$2.1 billion.

Co-investorsAisling CapitalARCH Venture PartnersProspect Venture PartnersSchooner CapitalALTITUDE LIFE SCIENCE VENTURESFoley Ventures

Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.

BiotechHealthtechSouth San Francisco, US

Aetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)inKaren Flick(General Counsel)in

Co-investorsREDMILEVersant VenturesBAM ElevateFranklin TempletonHBM Healthcare InvestmentsJanus Henderson Investors+4 more

BiotechWatertown, US

Carlo Giovanni Traverso(Director)Amy W. Schulman(Executive Officer, Director)inRobert S. Langer(Director)

BoardZafi Avnur(Director)Edmund Harrigan(Director)Catherine Reynolds(Director)

Co-investorsBill & Melinda Gates FoundationGilead SciencesKendall Capital PartnersPolaris Partners

A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.

Biotech

Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in

Co-investorsNextech InvestThird Rock VenturesAlexandriaCasdin CapitalCreacion VenturesGoldman Sachs+3 more

NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor.

BiotechHealthtechAustin, US

Gordon Freeman(Scientific Founder)XingXing Zang(Scientific Founder)inIvan Cheung(Chief Executive Officer)inLeena Gandhi(Chief Medical Officer)inTatiana Novobrantseva(Chief Scientific Officer)inAxel Hoos(Director)

Co-investorsCatalio Capital Management, LPMPM BioImpactSanofi VenturesCatalio Capital ManagementLeaps by BayerSixty Degree Capital

Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.

BiotechHealthtechMedical Devices

Ilise Lombardo(Chief Executive Officer)inVolker Knappertz(Executive Vice President of Research & Development)inMichael Samar(Chief Financial Officer)inRob Lasser(Chief Medical Officer)in

Co-investorsBioMedPartnersJeito CapitalRoche Venture FundSofinnova PartnersEQTEQT Life Sciences+2 more

PayJoy provides financial services and credit access to unbanked and underbanked populations in emerging markets across Africa, Asia, and Latin America.

B2B MarketplacesFintechImpact & Social GoodRetail TechSan Francisco, US

Mark Heynen(Co-Founder & Chief Business Officer)inDoug Ricket(Co-Founder & CEO)inGib Lopez(Co-Founder & COO)inTom Ricket(Co-Founder)inNick Zakrasek(President, Product Development)inAmy Pardee(General Counsel)in

Co-investorsCeniarthCiti VenturesCompoundCore Venture CapitalDnx VenturesEchoVC Partners+17 more

Restoring vision through optogenetics.

BiotechSan Francisco, US

Paul Bresge(Executive Officer, Director)Sean Ainsworth(Executive Officer, Director)

BoardTiba Aynechi(Director)inDmitry Kuzmin(Director)Raymond Camahort(Director)Hannah Chang(Director)

Co-investorsMRL Ventures Fund4BIO Capital4Bio VenturesDeerfield Management CompanyFranklin TempletonJanus Henderson Investors+2 more

Sironax is a biopharmaceutical company focused on the discovery and development of therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare diseases.

BiotechHealthtechLongevityWaltham, US

Dr. Xiaodong Wang(Founder)Dr. Zhiyuan Zhang(Founder)

Co-investorsARCH Venture PartnersF-Prime CapitalYuanBio Venture CapitalCBC GroupEight Roads VenturesFuture Innovation+5 more

Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.

BiotechDigital HealthHealthtech

Vishal Patelin

Co-investorsAtlas VentureBorealis VenturesBorealis VenturesMagnetic VenturesOrbiMedAscenta Capital+3 more